Evotec SE announced the initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail targeting orthopoxviruses. The program was developed by its subsidiary Just – Evotec Biologics under the U.S. Department of War’s Accelerated Antibodies Program in collaboration with BARDA. Manufacturing occurred at the company's J.POD® facility in Redmond using continuous bioprocessing. This contract is part of two agreements with a combined potential value of up to $123.9 million, following an initial 2022 award for plague antibodies. Evotec SE operates as a life science company pioneering drug discovery and development through AI-driven innovation and advanced technologies.

Evotec SE reported first-half 2026 Group revenues of €300.1 million, a 19.2% decline from the prior year period, driven by weak sales conversion and the non-recurrence of a Sandoz license sale in its Just – Evotec Biologics segment. Adjusted Group EBITDA widened to a loss of €42.7 million compared to a €1.9 million loss previously, impacted by €98.9 million in reorganization costs associated with the 'Horizon' transformation and a €42.3 million impairment of a Hamburg laboratory building. The company confirmed an updated full-year 2026 revenue outlook of €570–€610 million and adjusted EBITDA guidance of -€70 to -€105 million, reflecting lower expected contributions from strategic partnerships. Evotec operates in the life sciences industry, providing drug discovery and development services.